Roche Cuts Price Of Tarceva Cancer Med In UK
To get convince the UK’s National Institute for Health and Clinical Excellence to pay for its lung cancer treatment, Roche had to cut the price by about $1,000 in order to bring the cost more in line with Taxotere, an older medication sold by Sanofi-Aventis, Dow Jones tells us.
This entry was posted on Monday, October 6th, 2008 at 1:29 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.